Celltrion Presents the Long-Term Data for CT-P13 (biosimilar, infliximab) to Treat Inflammatory Bowel Disease (IBD) at ECCO 2024 

Shots: 

• The company presented 2yrs. results from the P-III (LIBERTY-CD) & (LIBERTY-UC) trial evaluating the superiority in safety & efficacy of CT-P13 (SC) vs Remicade in patients (n=180 & 237) with moderately to severely active CD & UC  

• In the trials, 85.6% & 87% of patients completed the extension phase with clinical remission, clinical response, endoscopic remission, endoscopic response & corticosteroid-free remission maintained at wk.102 vs wk.54 

• The company also presented a post hoc analysis evaluating the pattern of endoscopic mucosal healing across intestinal segments in patients enrolled in the P-III (LIBERTY-CD) trial. The results showed a significantly higher rate of endoscopic complete mucosal healing & partial mucosal healing with CT-P13 vs PBO 

Ref: Celltrion | Image: Celltrion| Press Release

Related News:- Samsung Bioepis Highlights 2 Abstracts for SB17 (biosimilar, ustekinumab) for the Treatment of Moderate-to-Severe Psoriasis at ECCO 2024  

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com